| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 70.72 | -0.48 (-0.67%) | 51.70 - 80.42 | 2.8 million (Below Avg) |
Market data as of 4:00PM 05/16/12. Quotes are delayed by at least 15 min.
| Open | 71.18 |
|---|---|
| Previous Close | 71.20 |
| Day's Range | 70.58 - 71.31 |
| Market Cap | 31.2B |
| Avg Volume (10 Day) | 3.1M |
| Price/Earnings (Trailing 12 Mo.) | 22.2x |
| Earnings Per Share (Trailing 12 Mo.) | 3.21 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Pass |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Le New England Journal of Medicine publie les résultats de trois essais de phase III de REVLIMID® (lénalidomide) effectués sur des patients atteints de myélome multiple nouvellement diagnostiqué
Business Wire - Thursday 05/10/2012 8:18 AM ET
New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly Diagnosed Multiple Myeloma
Business Wire - Thursday 05/10/2012 7:30 AM ET
Celgene Corporation Announces Appointment of Thomas M. Moriarty as General Counsel
Business Wire - Monday 05/07/2012 7:30 AM ET
Celgene Corporation to Present at Two Upcoming Investor Conferences
Business Wire - Friday 05/04/2012 7:30 AM ET
Epizyme Forms Strategic Partnership with Industry Leader in Epigenetic Therapies, Celgene Corporation, to Develop Personalized Therapeutics for Genetically-Defined Cancers
Business Wire - Thursday 04/26/2012 7:05 AM ET
Celgene Reports First Quarter 2012 Operating and Financial Results
Business Wire - Thursday 04/26/2012 7:00 AM ET
Celgene Corporation to Announce First Quarter 2012 Results on April 26, 2012
Business Wire - Tuesday 04/17/2012 7:30 AM ET
| CELG | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 26.02% | |
| Net Income Growth (1yr) | 62.38% | |
| Total Debt/Equity | 0.23 | |
| LT Debt/Equity | 0.21 | |
| Earnings Yield | 4.50% | |
| Price/Sales | 6.29 |
| Company | Last | Change |
|---|---|---|
| Gilead Sciences Inc | 51.58 | -0.56% |
| Shire PLC | 94.18 | -1.39% |
| Alexion Pharmaceuticals Inc | 86.99 | +0.30% |
| Vertex Pharmaceuticals Inc | 62.61 | -1.21% |
| Regeneron Pharmaceuticals Inc | 131.12 | +0.01% |
Data is delayed by at least 15 min.